Halozyme Therapeutics, Inc. $HALO Shares Bought by Envestnet Portfolio Solutions Inc.

Key Points

• Envestnet Portfolio Solutions Inc. increased its stake in Halozyme Therapeutics by 46.2%, bringing its total ownership to 16,506 shares valued at approximately $859,000.
• Several analysts have upgraded their ratings and price targets for Halozyme Therapeutics, with JMP Securities raising its price objective from $78.00 to $91.00 and Morgan Stanley adjusting it from $75.00 to $80.00.
• Insiders, including the CFO and CEO, recently sold shares of Halozyme Therapeutics, with total insider sales amounting to over $7.7 million in the last three months, indicating a significant decrease in their ownership positions.

Envestnet Portfolio Solutions Inc. lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 46.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 16,506 shares of the biopharmaceutical company's stock after purchasing an additional 5,214 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Halozyme Therapeutics were worth $859,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Isthmus Partners LLC boosted its position in shares of Halozyme Therapeutics by 2.5% in the 1st quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company's stock worth $439,000 after buying an additional 169 shares in the last quarter. OneDigital Investment Advisors LLC boosted its position in shares of Halozyme Therapeutics by 1.7% in the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock worth $649,000 after buying an additional 175 shares in the last quarter. Park Place Capital Corp boosted its position in shares of Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after buying an additional 182 shares in the last quarter. Xponance Inc. boosted its position in shares of Halozyme Therapeutics by 1.1% in the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock worth $1,190,000 after buying an additional 198 shares in the last quarter. Finally, Bessemer Group Inc. boosted its position in shares of Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 207 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on HALO shares. JMP Securities boosted their price objective on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 6th. Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research report on Monday, August 18th. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, October 14th. HC Wainwright restated a "buy" rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, October 15th. Finally, Wall Street Zen lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. Five analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $73.00.

Insider Transactions at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 20,000 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the transaction, the chief financial officer directly owned 24,306 shares in the company, valued at $1,840,207.26. This represents a 45.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $55,285,726.65. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 108,227 shares of company stock worth $7,779,595 in the last three months. Company insiders own 2.90% of the company's stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $67.03 on Monday. The firm has a market cap of $7.84 billion, a price-to-earnings ratio of 15.34, a price-to-earnings-growth ratio of 0.36 and a beta of 1.16. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $79.50. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The company's 50-day moving average is $71.56 and its two-hundred day moving average is $62.09.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. The business had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company's revenue was up 40.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.